2024
Neighborhood ethnoracial diversity and positive psychotic symptoms among youth at high-risk and healthy comparisons
Ku B, Yuan Q, Haardörfer R, Addington J, Bearden C, Cadenhead K, Cannon T, Cornblatt B, Keshavan M, Mathalon D, Perkins D, Stone W, Woods S, Druss B, Walker E, Anglin D. Neighborhood ethnoracial diversity and positive psychotic symptoms among youth at high-risk and healthy comparisons. Psychiatry Research 2024, 342: 116222. PMID: 39378539, DOI: 10.1016/j.psychres.2024.116222.Peer-Reviewed Original ResearchHealthy comparisonPositive symptomsCHR-PPeer victimizationNorth American Prodrome Longitudinal StudyScale of Prodromal SymptomsAttenuated positive symptomsPositive psychotic symptomsClinical high riskFewer life eventsAssociated with schizophreniaEthnoracial diversityPsychotic symptomsHigh riskPrevent psychosisDepressive symptomsStructural equation modelingLife eventsProdromal symptomsPsychosisDiscriminatory experiencesEthnoracial minoritiesSocial determinantsNeighborhood povertyEthnoracial groupsSex differences in clinical presentation in youth at high risk for psychosis who transition to psychosis
Chintoh A, Liu L, Braun A, Akseer S, Bearden C, Cadenhead K, Cornblatt B, Keshavan M, Mathalon D, McGlashan T, Perkins D, Seidman L, Stone W, Tsuang M, Walker E, Woods S, Cannon T, Addington J. Sex differences in clinical presentation in youth at high risk for psychosis who transition to psychosis. Schizophrenia Research 2024, 271: 153-160. PMID: 39029145, DOI: 10.1016/j.schres.2024.07.030.Peer-Reviewed Original ResearchClinical high riskClinical high-risk individualsSex differencesNegative symptomsTransition to psychosisInvestigate sex differencesNo sex differencesSchizophreniform disorderCHR individualsPsychosisSubstance useSchizophreniaSymptomsHigh riskIndividualsSchizophreniformAnxietyClinical presentationSexDepressionDisordersBaselineDifferencesMaleYouthThe Italian adaptation of the Mini‐SIPS, a tool for early detection of individuals at clinical high risk and first episode of psychosis: A preliminary study of implementation in an Italian FEP program
Ferrara M, Basaldella M, Vacca F, Woods S, Walsh B, Cannon T, Srihari V, Grassi L. The Italian adaptation of the Mini‐SIPS, a tool for early detection of individuals at clinical high risk and first episode of psychosis: A preliminary study of implementation in an Italian FEP program. Early Intervention In Psychiatry 2024 PMID: 38769052, DOI: 10.1111/eip.13548.Peer-Reviewed Original ResearchClinical high riskFirst-episode psychosisDSM-5-Attenuated Psychosis SyndromeItalian adaptationPsychosis syndromeDSM-5FEP programsEarly stages of psychosisItalian versionFirst-episode psychosis servicesFull-blown psychosisStages of psychosisEpisode of psychosisClinical structured interviewEpisode psychosisEstablished psychosisTrained psychologistsPsychiatric historyPsychosisPsychosis servicesHigh riskStructured interviewsClinical settingEarly detection of individualsAssess validitySocial Engagement Moderates Relations Between Hippocampal-Temporoparietal Junction Connectivity and Neighborhood Social Fragmentation in Youth at Clinical High Risk for Psychosis
Aberizk K, Addington J, Bearden C, Cadenhead K, Cannon T, Cornblatt B, Keshavan M, Mathalon D, Perkins D, Stone W, Tsuang M, Woods S, Walker E, Ku B. Social Engagement Moderates Relations Between Hippocampal-Temporoparietal Junction Connectivity and Neighborhood Social Fragmentation in Youth at Clinical High Risk for Psychosis. Biological Psychiatry 2024, 95: s37-s38. DOI: 10.1016/j.biopsych.2024.02.095.Peer-Reviewed Original Research451. Group Iterative Multiple Model Estimation Reveals Individuals at Clinical High-Risk for Psychosis and Healthy Comparisons Self-Organize by Premorbid Adjustment According to Patterns of Temporoparietal Brain Connectivity
Aberizk K, Ku B, Addington J, Bearden C, Cadenhead K, Cannon T, Cornblatt B, Keshavan M, Mathalon D, Perkins D, Stone W, Tsuang M, Woods S, Walker E. 451. Group Iterative Multiple Model Estimation Reveals Individuals at Clinical High-Risk for Psychosis and Healthy Comparisons Self-Organize by Premorbid Adjustment According to Patterns of Temporoparietal Brain Connectivity. Biological Psychiatry 2024, 95: s284. DOI: 10.1016/j.biopsych.2024.02.950.Peer-Reviewed Original ResearchAccelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis
Wannan C, Nelson B, Addington J, Allott K, Anticevic A, Arango C, Baker J, Bearden C, Billah T, Bouix S, Broome M, Buccilli K, Cadenhead K, Calkins M, Cannon T, Cecci G, Chen E, Cho K, Choi J, Clark S, Coleman M, Conus P, Corcoran C, Cornblatt B, Diaz-Caneja C, Dwyer D, Ebdrup B, Ellman L, Fusar-Poli P, Galindo L, Gaspar P, Gerber C, Glenthøj L, Glynn R, Harms M, Horton L, Kahn R, Kambeitz J, Kambeitz-Ilankovic L, Kane J, Kapur T, Keshavan M, Kim S, Koutsouleris N, Kubicki M, Kwon J, Langbein K, Lewandowski K, Light G, Mamah D, Marcy P, Mathalon D, McGorry P, Mittal V, Nordentoft M, Nunez A, Pasternak O, Pearlson G, Perez J, Perkins D, Powers A, Roalf D, Sabb F, Schiffman J, Shah J, Smesny S, Spark J, Stone W, Strauss G, Tamayo Z, Torous J, Upthegrove R, Vangel M, Verma S, Wang J, Rossum I, Wolf D, Wolff P, Wood S, Yung A, Agurto C, Alvarez-Jimenez M, Amminger P, Armando M, Asgari-Targhi A, Cahill J, Carrión R, Castro E, Cetin-Karayumak S, Chakravarty M, Cho Y, Cotter D, D’Alfonso S, Ennis M, Fadnavis S, Fonteneau C, Gao C, Gupta T, Gur R, Gur R, Hamilton H, Hoftman G, Jacobs G, Jarcho J, Ji J, Kohler C, Lalousis P, Lavoie S, Lepage M, Liebenthal E, Mervis J, Murty V, Nicholas S, Ning L, Penzel N, Poldrack R, Polosecki P, Pratt D, Rabin R, Eichi H, Rathi Y, Reichenberg A, Reinen J, Rogers J, Ruiz-Yu B, Scott I, Seitz-Holland J, Srihari V, Srivastava A, Thompson A, Turetsky B, Walsh B, Whitford T, Wigman J, Yao B, Yuen H, Ahmed U, Byun A, Chung Y, Do K, Hendricks L, Huynh K, Jeffries C, Lane E, Langholm C, Lin E, Mantua V, Santorelli G, Ruparel K, Zoupou E, Adasme T, Addamo L, Adery L, Ali M, Auther A, Aversa S, Baek S, Bates K, Bathery A, Bayer J, Beedham R, Bilgrami Z, Birch S, Bonoldi I, Borders O, Borgatti R, Brown L, Bruna A, Carrington H, Castillo-Passi R, Chen J, Cheng N, Ching A, Clifford C, Colton B, Contreras P, Corral S, Damiani S, Done M, Estradé A, Etuka B, Formica M, Furlan R, Geljic M, Germano C, Getachew R, Goncalves M, Haidar A, Hartmann J, Jo A, John O, Kerins S, Kerr M, Kesselring I, Kim H, Kim N, Kinney K, Krcmar M, Kotler E, Lafanechere M, Lee C, Llerena J, Markiewicz C, Matnejl P, Maturana A, Mavambu A, Mayol-Troncoso R, McDonnell A, McGowan A, McLaughlin D, McIlhenny R, McQueen B, Mebrahtu Y, Mensi M, Hui C, Suen Y, Wong S, Morrell N, Omar M, Partridge A, Phassouliotis C, Pichiecchio A, Politi P, Porter C, Provenzani U, Prunier N, Raj J, Ray S, Rayner V, Reyes M, Reynolds K, Rush S, Salinas C, Shetty J, Snowball C, Tod S, Turra-Fariña G, Valle D, Veale S, Whitson S, Wickham A, Youn S, Zamorano F, Zavaglia E, Zinberg J, Woods S, Shenton M. Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis. Schizophrenia Bulletin 2024, 50: 496-512. PMID: 38451304, PMCID: PMC11059785, DOI: 10.1093/schbul/sbae011.Peer-Reviewed Original ResearchClinical high-risk individualsClinical high riskNational Institute of Mental HealthInstitute of Mental HealthAttenuated positive symptomsPersistent negative symptomsTransition to psychosisCHR statusHigh riskNegative symptomsPositive symptomsAnxiety symptomsPsychosocial functioningCognitive dataOutcomes of individualsDigital health technologiesDaily surveysPsychosisSCZPublic health needsMental healthNovel pharmacological interventionsSchizophreniaClinical outcomesHealth needsDifferential expression of haptoglobin in individuals at clinical high risk of psychosis and its association with global functioning and clinical symptoms
Healy C, Byrne J, Raj Suasi S, Föcking M, Mongan D, Kodosaki E, Heurich M, Cagney G, Wynne K, Bearden C, Woods S, Cornblatt B, Mathalon D, Stone W, Cannon T, Addington J, Cadenhead K, Perkins D, Jeffries C, Cotter D. Differential expression of haptoglobin in individuals at clinical high risk of psychosis and its association with global functioning and clinical symptoms. Brain Behavior And Immunity 2024, 117: 175-180. PMID: 38219978, DOI: 10.1016/j.bbi.2023.12.018.Peer-Reviewed Original ResearchGlobal Assessment of Functioning ScaleNorth American Prodrome Longitudinal StudyClinical high riskPoor functionScale of Psychosis-risk SymptomsPsychosis-risk symptomsAssociated with poorer functioningFirst-episode psychosisTransition to psychosisGreater symptom severityFollow-upIndividuals at-riskClinical symptomsPsychotic disordersHigh riskSymptom severityPsychosocial functioningGlobal functioningPsychosisSubscale scoresFDR correctionAcute phase inflammatory responseLongitudinal studyGlobal assessmentFunctional scales
2014
Current status specifiers for patients at clinical high risk for psychosis
Woods SW, Walsh BC, Addington J, Cadenhead KS, Cannon TD, Cornblatt BA, Heinssen R, Perkins DO, Seidman LJ, Tarbox SI, Tsuang MT, Walker EF, McGlashan TH. Current status specifiers for patients at clinical high risk for psychosis. Schizophrenia Research 2014, 158: 69-75. PMID: 25012147, PMCID: PMC4152558, DOI: 10.1016/j.schres.2014.06.022.Peer-Reviewed Original ResearchConceptsNorth American Prodromal Longitudinal StudyClinical high-risk syndromeHigh-risk syndromeCurrent clinical statusPsychosis risk syndromeLongitudinal studyClinical high riskPartial remissionFull remissionClinical statusRemission criteriaRisk syndromeProgression criteriaRole functioningPredictive validityHigh riskRemitted patientsRemissionPatientsCurrent statusSyndromeConvergent validityPsychosisStructured interviewsPresent study
2013
Psychotropic medication use in youth at high risk for psychosis: Comparison of baseline data from two research cohorts 1998–2005 and 2008–2011
Woods SW, Addington J, Bearden CE, Cadenhead KS, Cannon TD, Cornblatt BA, Mathalon DH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, McGlashan TH. Psychotropic medication use in youth at high risk for psychosis: Comparison of baseline data from two research cohorts 1998–2005 and 2008–2011. Schizophrenia Research 2013, 148: 99-104. PMID: 23787224, PMCID: PMC3867209, DOI: 10.1016/j.schres.2013.05.019.Peer-Reviewed Original ResearchConceptsMedication use ratesCohort 2High riskCohort 1Alternative treatmentAntipsychotic prescription ratesBaseline antipsychotic useHigh-risk patientsEfficacy of antipsychoticsRate of prescriptionPsychotropic medication useChlorpromazine equivalent doseDuration of treatmentUse ratesNonpsychotic conditionsAntipsychotic dosesMedian ageMedication usePrescription ratesAntipsychotic prescriptionsAntipsychotic useAntipsychotic treatmentPsychotropic medicationsHigh-risk youthPsychiatric disorders